Zeria Pharmaceutical Co., Ltd. · TSE:4559
Zeria Pharmaceutical — H1 FY2025 Earnings Presentation
25 slides from Zeria Pharmaceutical's earnings presentation, Nov 11, 2025
Slide 1: Interim Financial Results Briefing
Fiscal Year Ending March 31, 2026 (Fiscal Year 2025) Interim Financial Results Briefing November 11, 2025 TSE Prime 4559 Zeria Pharmaceutical Co., Ltd. Mitsuhiro Ibe, Representative Director, President 1
Slide 2: I. Consolidated Interim Financial Highlights
I. Consolidated Interim Financial Highlights for Fiscal Year Ending March 31, 2026 (Fiscal Year 2025) I-1 Financial Overview I-2 Ethical Pharmaceuticals Business I-3 Consumer Healthcare Business I-4 Overseas Net Sales 2
Slide 3: I-1 Financial Overview: Final Year of the 11th Mid-Term Management Plan
I-1 Financial Overview Final Year of the 11th Mid-Term Management Plan (2023–2025) Management Targets Consolidated net sales: 90 billion yen Overseas net sales ratio: 50% or greater 11th Mid-Term Management Plan Main Policies Aim for further growth centered around a strong overseas business ① Cont
Slide 4: I-1 Financial Overview (2)
I-1 Financial Overview (2) Decrease in sales and profit due to rebound effects from Q4 in the previous fiscal year (Million yen) Fiscal Year Fiscal Year Difference Year-on- Forecast 2024 2025 with Publicly Year Announced Interim Interim Announced Difference in May Results Results Forecast Net Sales
Slide 5: I-1 Factors Causing Changes in Operating Profit
I-1 Financial Overview (3): Factors Causing Changes in Operating Profit - Year-on-Year Comparison (100 million yen) Year on year ¥2.8 billion decrease FY2024 Gross Labor Various Sales R&D Depreciation Other FY2025 Interim Period profit expenses fees promotion expenses expenses Interim Period Operati
Slide 6: I-2 Ethical Pharmaceuticals Business: Net Sales by Product
I-2 Ethical Pharmaceuticals Business: Net Sales by Product Decrease in sales due to rebound effects from Q4 in the previous fiscal year (Million yen) Fiscal Year 2024 Fiscal Year 2025 Interim Period Interim Period Year-on-Year Results Results Growth Rate Ethical Pharmaceuticals 28,544 26,208 -8.2% B
Slide 7: I-2 Net Sales by Product: Factors Causing Changes
I-2 Ethical Pharmaceuticals Business: Net Sales by Product Factors Causing Changes from Previous Year Year-on- Factors Causing Change Year Comparison Domestic Overseas (Million yen) (-) Rebound effect from significant Dificlir (+) Growth due to market -37 increase in shipments in Q4 in the (Dafclir)
Slide 8: I-3 Consumer Healthcare Business: Net Sales by Product
I-3 Consumer Healthcare Business: Net Sales by Product Marginal decrease overall despite continued strong performance by the Hepalyse range (Million yen) Fiscal Year 2024 Fiscal Year 2025 Interim Period Interim Period Year-on-Year Results Results Growth Rate Consumer Healthcare Business 13,802 13,67
Slide 9: I-3 Consumer Healthcare Net Sales: Factors Causing Changes
I-3 Consumer Healthcare Business: Net Sales by Product Factors Causing Changes from Previous Year Year-on-Year Comparison Factors Causing Change (Million yen) (+) Successful promotion of effects in countering fatigue Hepalyse Range Pharmaceuticals and exhaustion 453 Range (+) Launch of new product H
Slide 10: I-4 Overseas Net Sales
I-4 Overseas Net Sales Maintained overseas net sales ratio of 50% or greater Overseas Net Sales Ratio ■Overseas ■Domestic 50.3% 55.7% 54.5% Fiscal Year 2023 Fiscal Year 2024 Fiscal Year 2025 Interim Period Interim Period Interim Period Overseas Net Sales (Million yen) Fiscal Year 2023 Fiscal Year 20
Slide 11: II. Financial Forecast for Fiscal Year Ending March 31, 2026
II. Financial Forecast, etc. for Fiscal Year Ending March 31, 2026 (Fiscal Year 2025) II-1 Ethical Pharmaceuticals Business II-2 Consumer Healthcare Business II-3 Development Pipeline Status II-4 Consolidated Financial Forecast for Fiscal Year Ending Ending March March 31, 202631, 2026 II-5 Approach
Slide 12: II-1 Ethical Pharmaceuticals Business: Forecast for Second Half
II-1 Ethical Pharmaceuticals Business: Forecast for Second Half Overseas business to return to growth trajectory Quick market penetration of Veltassa in domestic business Overseas ethical pharmaceuticals Dificlir Reduced impact from significant shipment increases in Q4 in the previous fiscal year a
Slide 13: II-1 Overseas Ethical Pharmaceuticals: Dificlir
II-1 Overseas Ethical Pharmaceuticals Business: Dificlir Dificlir: Expected year-on-year growth of approximately 10% Dificlir Net Sales Trend (CHF) Expected return to growth trajectory due to easing of impact of FY2025 first-half net sales in major rebound effects from Q4 in the countries and region
Slide 14: II-1 Overseas Ethical Pharmaceuticals: Asacol
II-1 Overseas Ethical Pharmaceuticals Business: Asacol Asacol Net Sales Trend (CHF) FY2025 first-half net sales in major countries and regions ■2024 ■2025 Increases in our largest markets in the Four countries in Northern Europe UK, France, and Germany UK Significant decreases in Northern Europe
Slide 15: II-1 Overseas Ethical Pharmaceuticals: Asacol 1600 mg
II-1 Overseas Ethical Pharmaceuticals Business: Asacol Asacol: Expected return to previous fiscal year levels Asacol 1600 mg Net Sales Trend (CHF) FY2025 first-half net sales in major countries and regions ■2024 ■2025 Four countries in Northern Continued strong performance from Europe previous yea
Slide 16: II-1 Domestic Ethical Pharmaceuticals: Veltassa
II-1 Domestic Ethical Pharmaceuticals Business: Veltassa Increase in market share for the therapeutic agent of hyperkalemia Veltassa First-half activities Proactive information sharing activities, including online lectures and other digital marketing efforts, primarily for doctors specializing in
Slide 17: II-2 Consumer Healthcare Business: Forecast for Second Half
II-2 Consumer Healthcare Business: Forecast for Second Half Hepalyse to continue to drive strong performance Sales of Chondroitin also expected to increase Hepalyse Range Launch of new products, primarily pharmaceuticals (tablets), that are expected to further increase sales Chondroitin Range Shif
Slide 18: II-2 Consumer Healthcare Business: Hepalyse Range
II-2 Consumer Healthcare Business: Hepalyse Range Hepalyse Range Net Sales Trend (Million yen) W Range and Hepalyse Range Expected year-on-year growth Others Surpassed pre-COVID-19 Pharmaceuticals Range pandemic net sales levels of around 10% Pharmaceuticals 6,122 Continue to promote effects in co
Slide 19: II-2 Chondroitin Range: Investment in Production Equipment at ZPD
II-2 Consumer Healthcare Business: Chondroitin Range Investment in Chondroitin production equipment at ZPD Reinforcement of production equipment for increased production of pharmaceutical-grade Chondroitin in line with the European Pharmacopoeia Denmark ZPD A/S The aim is to ensure stable supplies
Slide 20: II-3 Development Pipeline Status
II-3 Development Pipeline Status Domestic Development Development Development NDA NDA Company/ Indication Phase 1 Phase 2 Phase 3 Launch Code/Name Filed Approved Institution ZG-801 Zeria Hyperkalemia Launch of Veltassa on March 17, 2025 Z-338 Pediatric functional Zeria (Acotiamide) dyspepsia ZG-802
Slide 21: II-3 Specific Clinical Study of Z-100
II-3 Development Pipeline Status - Specific Clinical Study of Z-100 Recent Z-100 Activity Implemented Phase III international joint clinical trials in seven Asian countries and regions, including Japan, for the treatment of cervical cancer from 2014 onward Removed Z-100 from pipeline in 2021 follo
Slide 22: II-4 Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026
II-4 Consolidated Financial Forecast for Fiscal Year Ending March 31, 2026 (Million yen) Fiscal Year Ended Fiscal Year Ending March 31, 2026 March 31, 2025 Year-on-Year Results Expectation Growth Rate Net Sales 87,311 90,000 3.1% Operating Profit 12,197 12,000 -1.6% Ordinary Profit 12,840 12,000 -6.
Slide 23: II-5 Approach to Dividends and Shareholder Returns
II-5 Approach to Dividends and Shareholder Returns With a focus on maintaining stable dividends, dividends will be paid in line with financial performance Dividend increases for five consecutive terms Interim dividend 48.00 yen 50.00円 50.00 yen Year-end dividend 47.00 yen (expected) 44.00 yen 40.00
Slide 24: II-6 Toward the 12th Mid-Term Management Plan
II-6 Toward the 12th Mid-Term Management Plan Zeria Pharmaceutical celebrates its 70th anniversary in December this year • The Company started with the manufacture and sale of Chondroitin-containing cosmetics and then began sales of Chondroitin and Hepalyse, which are the core products in today’s C
Slide 25: This document includes statements related to future performance. These statements are not a guarantee
This document includes statements related to future performance. These statements are not a guarantee of future performance and include risks and uncertainties. Please keep in mind that future business results may differ from expectations due to changes in the business environment and other factors.
Zeria Pharmaceutical — H1 FY2025 Earnings Presentation on 6ix